



Northern Treatment
Advisory Group

Northern (NHS) Treatment Advisory Group

Current Work plan

Drug	Details	Provisional Meeting Date
Lurasidone in Bipolar Depression	Unlicensed indication	TBC
Inhaled levodopa for Parkinson's disease – not in in NICE workplan	New formulation as alternative to apomorphine. Not in NICE timetable.	On hold awaiting launch in UK of product.
Sublingual apomorphine for Parkinson's disease	New oral formulation. License expected 2023 Not in in NICE timetable.	TBC – depends on licensing/launch date
Intranasal adrenaline for anaphylaxis	Not in in NICE timetable.	TBC – depends on licensing/launch date
Osteoporosis guidelines	To develop regional guideline around latest NOGG guideline	July 2023 following NENC consultation in May/June 2023.
National Shared Care Guideline templates including NENC DMARD share care guidelines	To consider regional adoption via a regional working group which will report back to NTAG.	Amiodarone – awaiting final draft post consultation plus engagement with cardiac network. DMARDs – awaiting ICB decision on model(s) of provision of DMARD shared care in NENC.
Regional menopause guideline	To develop approved Tyne & Wear guideline as regional guideline	July 2023 following NENC consultation in May/June 2023.
NHSE Operational Note – Blood Glucose/ketone test strips and lancets	To consider proposal from NENC ICB on updating the NENCformulary.	TBC
Formulary applications <ul style="list-style-type: none"> Ovamex® Spironolactone for dermatology Riluzole (Emlif®) 50 mg orodispersible film 	To consider these new formulary applications.	July 2023

Potential Topics for re-review

Subcutaneous infliximab	To review this recommendation when ICS commissioning structures are more established and there is clarity on the ICS funding arrangements for high cost drugs.
-------------------------	--

NTAG
May 2023